ESP vs SPSIP Block in VATS Analgesia
Comparison of the Effects of Ultrasound-Guided Erector Spinae Plane Block and Serratus Posterior Superior Intercostal Plane Block on Postoperative Analgesia Management in Patients Undergoing Video-Assisted Thoracoscopic Surgery
1 other identifier
interventional
90
1 country
1
Brief Summary
Video-assisted thoracoscopic surgery (VATS) is a minimally invasive procedure performed through small thoracic incisions, but postoperative pain remains significant due to tissue and rib trauma. Poorly controlled pain may lead to chronic postoperative pain; therefore, optimal analgesia is essential. According to PROSPECT guidelines, erector spinae plane block (ESPB) or paravertebral block (PVB) are recommended for VATS. The recently defined serratus posterior superior intercostal plane block (SPSIPB) provides analgesia between C3-T10 levels, but its efficacy compared with ESPB has not been studied. This study aims to compare postoperative analgesic efficacy and patient satisfaction between ESPB and SPSIPB in VATS patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 14, 2025
CompletedStudy Start
First participant enrolled
November 15, 2025
CompletedFirst Posted
Study publicly available on registry
November 18, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2026
CompletedDecember 16, 2025
December 1, 2025
6 months
November 14, 2025
December 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
opioid consumption
Tramadol will be prepared as 5mg/ml and patient-controlled analgesia will be administered without basal infusion, with a locking time of 20 minutes and a bolus dose of 10mg.
0, 2, 4, 8, 16 and 24 hours
Secondary Outcomes (4)
Postoperative pain scores (Numerical rating scale) (0-meaning "no pain" to 10-meaning "worst pain imaginable")
0, 2, 4, 8, 16 and 24 hours
Global recovery scoring system (patient satisfaction scale)- QoR-15
The quality of recovery will be evaluated out of a total of 150 points according to the QoR-15 test to be applied at the portoperative 24th hour.
Brief Pain Inventory
postoperative third month
Hospital Anxiety and Depression Scale (HADS)
On the morning of surgery and at the 3rd postoperative month
Study Arms (2)
Serratus posterior superior intercostal plane block (SPSIPB)
ACTIVE COMPARATORErector spinae plane block
ACTIVE COMPARATORInterventions
A high-frequency linear ultrasound probe (GE ML6-15-D Matrix Linear) will be covered with a sterile sheath, and the T3 level will be identified just above the medial border of the scapula. After visualizing the trapezius, rhomboid major, and serratus posterior superior muscles (from superficial to deep), 30 mL of 0.25% bupivacaine (Buvicaine 0.5%®, Polifarma, Tekirdağ, Türkiye) containing 7.5 µg epinephrine (1:200,000) (Adrenalin Bas Galen®; Galen, İstanbul, Türkiye) will be administered as the local anesthetic solution.
A high-frequency linear ultrasound probe (GE ML6-15-D Matrix Linear) will be covered with a sterile sheath. At the T5 vertebral level, the erector spinae muscle layers and the transverse process of the T5 vertebra, located immediately beneath them, will be identified. After confirming the transverse process, 30 mL of 0.25% bupivacaine (Buvicaine 0.5%®, Polifarma, Tekirdağ, Türkiye) containing 7.5 µg epinephrine (1:200,000) (Adrenalin Bas Galen®; Galen, İstanbul, Türkiye) will be administered as the local anesthetic solution.
Eligibility Criteria
You may qualify if:
- Patients aged 18-65 years with ASA physical status I-III who will undergo elective video-assisted thoracoscopic surgery (VATS) will be included.
You may not qualify if:
- Patients who do not consent to participate in the study
- Patients with coagulopathy
- Patients with a history of local anesthetic allergy or toxicity
- Patients with hepatic or renal failure
- Patients with uncontrolled diabetes
- Patients with uncontrolled hypertension
- Mentally disabled patients
- Patients receiving chronic pain treatment (opioid users)
- Patients using antidepressant medication
- Patients with neuropathic pain
- Mentally disabled patients
- Presence of infection at the injection site
- Pregnant or breastfeeding women, or those with suspected pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bursa City Hospitallead
- Emre ULUSOYcollaborator
Study Sites (1)
Bursa City Hospital
Bursa, Nilüfer, 16110, Turkey (Türkiye)
Related Publications (3)
Mehta S, Jen TTH, Hamilton DL. Regional analgesia for acute pain relief after open thoracotomy and video-assisted thoracoscopic surgery. BJA Educ. 2023 Aug;23(8):295-303. doi: 10.1016/j.bjae.2023.05.001. Epub 2023 Jun 22. No abstract available.
PMID: 37465231BACKGROUNDWong MKH, Sit AKY, Au TWK. Minimally invasive thoracic surgery: beyond surgical access. J Thorac Dis. 2018 Jun;10(Suppl 16):S1884-S1891. doi: 10.21037/jtd.2018.05.196.
PMID: 30026975BACKGROUNDSteinthorsdottir KJ, Wildgaard L, Hansen HJ, Petersen RH, Wildgaard K. Regional analgesia for video-assisted thoracic surgery: a systematic review. Eur J Cardiothorac Surg. 2014 Jun;45(6):959-66. doi: 10.1093/ejcts/ezt525. Epub 2013 Nov 27.
PMID: 24288340BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- assoc prof
Study Record Dates
First Submitted
November 14, 2025
First Posted
November 18, 2025
Study Start
November 15, 2025
Primary Completion
May 15, 2026
Study Completion
May 15, 2026
Last Updated
December 16, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be shared